BioAtla (BCAB) Competitors $0.37 +0.01 (+1.63%) As of 10:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB vs. ANRO, SKYE, ALGS, ADAP, IMAB, ENTX, EPIX, ALTS, ZIVO, and SCLXShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Alto Neuroscience (ANRO), Skye Bioscience (SKYE), Aligos Therapeutics (ALGS), Adaptimmune Therapeutics (ADAP), I-Mab (IMAB), Entera Bio (ENTX), ESSA Pharma (EPIX), Janone (ALTS), ZIVO Bioscience (ZIVO), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Alto Neuroscience Skye Bioscience Aligos Therapeutics Adaptimmune Therapeutics I-Mab Entera Bio ESSA Pharma Janone ZIVO Bioscience Scilex BioAtla (NASDAQ:BCAB) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, community ranking, earnings and dividends. Does the media favor BCAB or ANRO? In the previous week, Alto Neuroscience had 19 more articles in the media than BioAtla. MarketBeat recorded 22 mentions for Alto Neuroscience and 3 mentions for BioAtla. BioAtla's average media sentiment score of 0.97 beat Alto Neuroscience's score of 0.75 indicating that BioAtla is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAtla 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, BCAB or ANRO? Alto Neuroscience has lower revenue, but higher earnings than BioAtla. Alto Neuroscience is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAtla$11M1.65-$123.46M-$1.70-0.22Alto NeuroscienceN/AN/A-$36.31M-$2.54-0.99 Do analysts recommend BCAB or ANRO? BioAtla presently has a consensus target price of $6.00, suggesting a potential upside of 1,495.74%. Alto Neuroscience has a consensus target price of $16.75, suggesting a potential upside of 563.10%. Given BioAtla's higher probable upside, research analysts plainly believe BioAtla is more favorable than Alto Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is BCAB or ANRO more profitable? Alto Neuroscience's return on equity of -49.28% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets BioAtlaN/A -187.30% -96.33% Alto Neuroscience N/A -49.28%-33.52% Does the MarketBeat Community favor BCAB or ANRO? BioAtla received 10 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 83.33% of users gave Alto Neuroscience an outperform vote while only 67.57% of users gave BioAtla an outperform vote. CompanyUnderperformOutperformBioAtlaOutperform Votes2567.57% Underperform Votes1232.43% Alto NeuroscienceOutperform Votes1583.33% Underperform Votes316.67% Do institutionals and insiders hold more shares of BCAB or ANRO? 77.2% of BioAtla shares are held by institutional investors. 11.5% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryBioAtla beats Alto Neuroscience on 8 of the 14 factors compared between the two stocks. Remove Ads Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.18M$3.02B$5.65B$8.24BDividend YieldN/A1.54%4.55%4.02%P/E Ratio-0.2229.3524.5519.21Price / Sales1.65440.51386.5595.29Price / CashN/A168.6838.1634.64Price / Book0.264.207.024.43Net Income-$123.46M-$71.72M$3.20B$247.19M7 Day Performance5.62%-4.47%-1.37%-0.05%1 Month Performance9.94%-10.96%3.17%-4.55%1 Year Performance-87.51%-23.86%13.85%4.50% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla3.3151 of 5 stars$0.37+1.6%$6.00+1,508.6%-84.2%$18.03M$11M-0.2260Upcoming EarningsGap UpANROAlto Neuroscience2.3616 of 5 stars$2.65-0.2%$16.75+533.3%-84.6%$71.34MN/A-1.04N/AEarnings ReportAnalyst RevisionSKYESkye Bioscience1.0742 of 5 stars$2.35+4.4%$18.00+666.0%-82.4%$71.29MN/A-3.2611Earnings ReportGap DownALGSAligos Therapeutics4.1192 of 5 stars$11.63+8.2%$70.00+501.9%-54.2%$71.11M$3.95M-0.8790Gap UpADAPAdaptimmune Therapeutics2.18 of 5 stars$0.28-4.8%$2.18+687.6%-82.6%$70.83M$175.04M-1.26490Earnings ReportNews CoverageIMABI-Mab3.281 of 5 stars$0.87+2.0%$7.00+706.6%-53.2%$70.73M$3.27M0.00380Upcoming EarningsENTXEntera Bio2.1382 of 5 stars$1.95flat$10.00+412.8%+20.5%$69.78M$99,000.00-7.5020Upcoming EarningsEPIXESSA Pharma3.1206 of 5 stars$1.56-1.3%$9.50+509.0%-82.9%$69.25MN/A-2.2650ALTSJanoneN/A$4.91+3.8%N/AN/A$69.08M$7.11M0.00170Positive NewsZIVOZIVO BioscienceN/A$18.00+5.3%N/A+111.4%$67.30M$15,850.00-3.6910Gap DownSCLXScilex1.6082 of 5 stars$0.28-1.5%$14.00+4,972.5%-82.9%$67.15M$55.15M-0.3380Upcoming EarningsGap Up Remove Ads Related Companies and Tools Related Companies ANRO Alternatives SKYE Alternatives ALGS Alternatives ADAP Alternatives IMAB Alternatives ENTX Alternatives EPIX Alternatives ALTS Alternatives ZIVO Alternatives SCLX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAB) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
